This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
== G == G protein - G protein-coupled receptor - G3P - GABA - GABA receptor - GABA-A receptor - gag-onc fusion protein - galanin - gamete - gamma-chain immunoglobulin - gamma-delta T-cell antigen receptor - gastrin - gastrointestinal hormone receptor - gastrula - gel electrophoresis - gene - gene expression - gene pool - gene regulatory network - genetic carrier - genetic code - genetic drift - genetic engineering - genetic fingerprint - genetic recombination - genetics - genome - genomics - genotype - glial fibrillary acidic protein - globin - glucagon - glucagon receptor - glucocorticoid receptor - glucose - glutamate - glutamate receptor - glutamic acid - glutamine - glycerine - glycine - glycine receptor - glycolipid - glycolysis - glycoprotein - gonadorelin - gradient - granulocyte colony-stimulating factor - granulocyte colony-stimulating factor receptor - granulocyte-macrophage colony-stimulating factor - granulocyte-macrophage colony-stimulating factor receptor - granzyme - growth factor receptor - GTP-binding protein - GTPase
plant-based products such as opium and its derivatives morphine, codeine, and heroin (the primary category of drug listed in the convention); synthetic narcotics such as methadone and pethidine; and cannabis, coca, and cocaine. The Convention divides drugs into four groups, or schedules, to enforce a greater or lesser degree of control for the various substances and compounds. Opium smoking and eating, coca leaf chewing, cannabis resin smoking, and the non-medical use of cannabis are prohibited. The 1972 Protocol to this Convention calls for increased efforts to prevent illicit production of, traffic in, and use of narcotics as defined by the convention, while highlighting the need to provide treatment and rehabilitation services to drug abusers.
=== Approval rate === While over 150 cerebroprotectants have been tested in clinical trials, as of 2022 only the above two cerebroprotectants are approved, though several clinical trials for other drugs are ongoing. The approval rate has been less than 2%, which is low compared to the overall approval rate of all drugs brought into clinical trials in all disease areas from 2011 to 2022 which was 7.9%. It is also much lower than the relatively high success rate for devices to treat acute ischemic stroke, as there have been at least 5 different clot removal devices approved since 2015.
=== Structural and political accounts === From the early 1980s, critical medical anthropology was applied to drug use, shifting attention from cultural meaning to the political and economic structures within which drug use occurs: political systems, economic inequality, and institutional power over social processes. The approach emphasises three themes — self-medication of the distress produced by social inequality and injustice; the social production of suffering, meaning the ill health and hardship concentrated among those with least power; and the political economy of licit and illicit drug markets. On this view, heavy drug use and addiction are consequences of these larger-scale inequalities in power.
Sources: en.wikipedia.org
=== Weight loss === Excess body weight is thought to be an important cause of sleep apnea. People who are overweight have more tissues in the back of their throat which can restrict the airway, especially when sleeping. In weight loss studies of overweight individuals, those who lose weight show reduced apnea frequencies and improved apnoea–hypopnoea index (AHI). Weight loss effective enough to relieve obesity hypoventilation syndrome (OHS) must be 25–30% of body weight. For some obese people, it can be difficult to achieve and maintain this result without bariatric surgery.
The development of the human lungs arise from the laryngotracheal groove and develop to maturity over several weeks in the foetus and for several years following birth. The larynx, trachea, bronchi and lungs that make up the respiratory tract, begin to form during the fourth week of embryogenesis from the lung bud which appears ventrally to the caudal portion of the foregut.
– that is the probability of a molecule to have energy greater than or equal to E at the given temperature T. This exponential dependence of a reaction rate on temperature is known as the Arrhenius equation. The activation energy necessary for a chemical reaction to occur can be in the form of heat, light, electricity or mechanical force in the form of ultrasound. A related concept free energy, which also incorporates entropy considerations, is a very useful means for predicting the feasibility of a reaction and determining the state of equilibrium of a chemical reaction, in chemical thermodynamics. A reaction is feasible only if the total change in the Gibbs free energy is negative,
Sources: en.wikipedia.org
4-HO-DPT, also known as 4-hydroxy-N,N-dipropyltryptamine or as deprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. The drug is closely structurally related to other psychedelic tryptamines such as dipropyltryptamine (DPT), 5-MeO-DPT, and psilocin (4-HO-DMT), among others. 4-HO-DPT was first described in the scientific literature by David Repke and colleagues in 1977. It was encountered as a novel designer drug in 2012. A presumed prodrug, 4-AcO-DPT, is also known, and has likewise been encountered as a designer drug.
12 September – Bill Wilson, lawyer and judge, judge of the Court of Appeal (2007–2008) and Supreme Court (2008–2010), King's Counsel (since 1996) (born 1946). 13 September – Stan Simpson, wool scientist (WRONZ) and science administrator, director of WRONZ (1978–1992) (born 1933). 14 September – Barry Roberts, cricketer (Northern Districts) (born 1946). 16 September Judy Tinnock, tennis player, Wimbledon mixed doubles semi-finalist (1954) (born 1931). Jack Williams, cricketer (Canterbury) (born 1931). 17 September Tenick Dennison, paediatrician, conservationist and ornithologist (born 1927). Jim Easton, oldest living man in New Zealand (108 years, 279 days), oldest living Australian World War II veteran (born 1916). Dame Joan Metge, social anthropologist (University of Auckland, Victoria University of Wellington), Te Rangi Hiroa Medal (1997) (born 1930). 20 September – Tui Te Rupe, Paralympic marathon runner (1988) (born 1943). 21 September Stu Freebairn, rugby union player (Manawatu, national team) (born 1932). William E. Shepard, religious studies academic (University of Canterbury) (born 1933). 22 September Ian Farquhar, maritime historian, businessman and local politician, chair of the Otago Harbour Board (1980–1983) (born 1931). Grant Hawke, Māori leader (Ngāti Whātua Ōrākei) (born 1944). 23 September Bruce Morrison, cricketer (Wellington, national team) (born 1933). Sir Tumu Te Heuheu, Māori leader, paramount chief of Ngāti Tūwharetoa (since 1997) (born 1941). 25 September Glynn Jones, physicist (University of Canterbury) (born 1936).
=== Nobel Prize in Physiology or Medicine (1923) === In October 1923, Banting and Macleod were jointly awarded the 1923 Nobel Prize in Physiology or Medicine "for the discovery of insulin". Within a month of the award ceremony, Banting had given Best one-half of his share in the $US24,000 prize, and Macleod had given Collip one-half of his share.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.